ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

inavolisib

Also written as “Inavolisib”, “Inavolisib (Dose #1)” and “Inavolisib (Dose #2)”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Neoplasms · Prostatic Neoplasms · Neoplasm Metastasis, led by Hoffmann-La Roche.

Drug pageInavolisib: every studyAll 32 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 2, 201920 company-led studies, 17 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche2017 open or runningphase 3since Dec 2, 2019Dec 22, 2016Dec 31, 2026phase 1 · NCT03006172

Also a collaborator on its studies: Gilead Sciences and Pfizer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 5 earlier studies, Dec 22, 2016 to Nov 12, 2020.

  1. Dec 9, 2019Named inavolisibINNProposed as its International Nonproprietary Name in WHO's List 122
  2. Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
  3. Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
  4. Jun 11, 2021Phase 1 study in Colorectal NeoplasmsNCT04929223 · 542 planned · United States, Australia, Canada and more
  5. Dec 2, 2022Phase 3 study in Breast NeoplasmsNCT05646862 · 420 planned · United States, Argentina, Australia and more
  6. May 1, 20232 phase 3 studiesNCT05862285, NCT05894239
  7. Jul 4, 2024Phase 1 study in PIK3CA-Mutated CancersNCT06496568 · 30 enrolled · United States, Canada, South Korea
  8. Jan 14, 2025Phase 3 study in Breast NeoplasmsNCT06790693 · 450 planned · United States, Argentina, Australia and more
  9. Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
  10. Aug 20, 2025Phase 1 study in Hepatic ImpairmentNCT07144111 · 27 enrolled · United States
  11. Dec 11, 2025Phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT07287150 · 100 planned · United States, Australia, Brazil and more
  12. Jan 6, 20262 phase 2 studiesNCT07323576, NCT07368998
  13. Feb 6, 2026Phase 2 study in Breast NeoplasmsNCT07405801 · 80 planned · United States, Argentina, Brazil and more
  14. Jul 20, 2026Phase 2 study in Breast NeoplasmsNCT07748208 · 40 planned · United States, Puerto Rico
  15. Nov 13, 2026Primary completion moved from 2026-12-31 to 2027-05-03Date moved laterphase 3 · +4 months · NCT05894239

Ahead

  1. Nov 13, 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05646862
  2. Dec 31, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT03006172
  3. May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05894239
  4. Jul 21, 2027Primary completion: phase 1 study in PIK3CA-Mutated CancersNCT06496568

TargetBeta

PIK3CA →read by rule
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
AlpelisibruleNovartisphase 437
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07748208Breast Neoplasms · United States, Puerto Rico2RecruitingJun 15, 202940
NCT07405801Breast Neoplasms · United States, Argentina, Brazil and more2RecruitingDec 19, 202880
NCT07368998Breast Neoplasms · United States, Argentina, Australia and more2RecruitingOct 31, 202880
NCT07323576Colorectal Neoplasms2WithdrawnMar 1, 20290
NCT07287150Metastatic Castration-Resistant Prostate Cancer · United States, Australia, Brazil and more2RecruitingMar 31, 2028100
NCT07144111Hepatic Impairment · United States1CompletedOct 13, 202627
NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more2RecruitingJul 31, 2027120
NCT06790693Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJan 31, 2032450
NCT06496568PIK3CA-Mutated Cancers · United States, Canada, South Korea1Active, not recruitingJul 21, 202730
NCT05894239Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMay 3, 2027230
NCT05862285Neoplasms · Belgium, Canada, China and more3RecruitingMar 1, 2033200
NCT05646862Breast Neoplasms · United States, Argentina, Australia and more3RecruitingNov 13, 2026420
NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more1RecruitingAug 31, 2030542
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingFeb 28, 2028176
NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more2RecruitingMay 30, 2029316
NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States2CompletedDec 4, 2023252
NCT04589845Solid Tumors · United States, Australia, Belgium and more2Active, not recruitingSep 25, 2032920
NCT04191499Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingSep 29, 2023325
NCT03424005Breast Neoplasms · United States, Australia, France and more2RecruitingSep 30, 20301,132
NCT03006172Breast Neoplasms · United States, Canada, France and more1Active, not recruitingDec 31, 2026200

How it is read

Names in the registry

  • “Inavolisib”, 20 entries
  • “Inavolisib (Dose #1)”, 1 entry
  • “Inavolisib (Dose #2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.